The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

  • H. M. Zhu*
  • , L. Qin*
  • , P. Garnero
  • , H. K. Genant
  • , G. Zhang
  • , K. Dai
  • , X. Yao
  • , G. Gu
  • , Y. Hao
  • , Z. Li
  • , Y. Zhao
  • , W. Li
  • , J. Yang
  • , X. Zhao
  • , D. Shi
  • , T. Fuerst
  • , Y. Lu
  • , H. Li
  • , X. Zhang
  • , C. Li
  • J. Zhao, Q. Wu, S. J. Zhao
*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

99 Citations (Scopus)

Abstract

Summary This multicenter and randomized clinical trial showed that daily oral herbal formula Xian Ling Gu Bao (XLGB) was safe in postmenopausal women over a 1-year treatment. Those patients (n-50) treated with XLGB at the conventional dose demonstrated a statistically significant increase in dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) at lumbar spine at 6 months and a numerically increased BMD at 12 months. Introduction The aim of this study was to examine the safety and efficacy of a herbal formula XLGB in postmenopausal women (ChiCTR-TRC-00000347). Methods One hundred eighty healthy postmenopausal women (≫60 years old) with BMD T-score-2.0 (lumbar spine or femoral neck) were recruited from four clinical centers to receive low-dose (conventional dose) XLGB (L-XLGB group, 3 g/day, n=61) or high-dose XLGB (H-XLGB group, 6 g/day, n=58) or placebo (CON group, n=61). Women received daily calcium (500 mg) and vitamin D (200 IU) SUPPL.ementation. Primary endpoints were lumbar spine BMD and safety; secondary endpoints were femoral neck BMD and bone turnover markers measured at baseline and at 6 and 12 months. Results Of 180 women recruited, 148 completed the study. The compliance in each group was comparable. Prominent adverse events were not observed in either group. In the L-XLGB group at 6 months, lumbar spine BMD by DXA increased significantly from baseline (+2.11% versus CON +0.58%, p<0.05), but femoral neck BMD did not; at 12 months, BMD in the L-XLGB group decreased from 6-month levels yet remained higher than baseline, but without difference from the CON group. There was no dose-dependent response. Bone turnover marker levels declined during the first 6 months after XLGB treatment. There was no significant difference in the overall incidence of side effects among treatment and control groups. Conclusion XLGB over 1-year treatment at the conventional dose demonstrated safe and only a statistically significant increase in BMD at lumbar spine at 6 months in postmenopausal women.

Original languageEnglish
Pages (from-to)1317-1327
Number of pages11
JournalOsteoporosis International
Volume23
Issue number4
DOIs
Publication statusPublished - Apr 2012

User-Defined Keywords

  • Chinese herb
  • Clinical trial
  • Osteoporosis

Fingerprint

Dive into the research topics of 'The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis'. Together they form a unique fingerprint.

Cite this